Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Memorial Sloan Kettering Cancer Center

427 clinical trials

470 abstracts

30 posters

Poster
Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Tumor Volume and T2 Hyperintensity Changes from DeFi: A Phase 3, Randomized, Controlled Trial of Nirogacestat in Patients With Desmoid Tumors
Poster
The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Poster
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Poster
Clinical Significance Of CTC Enumeration Using The Epic Sciences Platform In Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated With AR Signaling Inhibitors
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Circulating Tumor Cells (CTCs) With Small-Cell Like Features are Prevalent in Metastatic Castration Resistant Prostate Cancer (mCRPC) and Show Selective Pharmacodynamic Reductions in Patients Treated With Platinum Therapy but not an ARSi or Taxane
Poster
The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Poster
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Poster
CTC Number Determined on the Epic Sciences Platform is Prognostic For Survival and Time on ARSi Treatment for mCRPC patients
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Circulating Tumor Cells (CTCs) With Small-Cell Like Features in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Poster
The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Poster
Tumor Volume and T2 Hyperintensity Changes from DeFi: A Phase 3, Randomized, Controlled Trial of Nirogacestat in Patients With Desmoid Tumors
Poster
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Poster
CTC Number Determined on the Epic Sciences Platform is Prognostic For Survival and Time on ARSi Treatment for mCRPC patients
Poster
Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
Poster
A phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations
Poster
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions
Poster
MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)
Poster
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (GIST)
Poster
Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib
Poster
Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors
Poster
Tip-NRG1 MCLA-128-CL01
Poster
Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) non-small cell lung cancer (NSCLC)
Poster
Impact of Nirogacestat on Functional Status in Patients with Desmoid Tumors: Results From the Phase 3 DeFi Study
Poster
Phase 2 study of Zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
Poster
Impact of Nirogacestat on Pain, a Key Symptom in Patients With Desmoid Tumors: Results From the Phase 3 DeFi Study
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.
Org: Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Next Oncology Virginia and Virginia Cancer Specialists, AbbVie Inc., Sarah Cannon Research Institute at Tennessee Oncology, PLLC,
Abstract
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
Org: Sylvester Comprehensive Cancer Center, University of Miami Health System, The University of Texas MD Anderson Cancer Center, HonorHealth Research Institute, University of California, San Francisco, Baylor College of Medicine,
Abstract
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
Org: Humanity and Health Clinical Trial Center, Liver Unit and HPB Oncology Area, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Barcelona Clinic Liver Cancer,
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.
Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Org: Memorial Sloan Kettering Cancer Center, Kyushu University, University Hospital Essen, P.A. Herzen Moscow Oncological Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.
Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,
Abstract
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
Org: Memorial Sloan Kettering Cancer Center, Niigata University Graduate School of Medical and Dental Sciences, ICON Research, Bristol Myers Squibb, West-German Cancer Center Essen,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Org: O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Clinical Trial Development Division, Roswell Park Comprehensive Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center,
Abstract
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Org: Agomab Spain, LMU Munich, The Jikei University School of Medicine, Co-ordinating Center for Clinical Trials of the Philipps-University of Marburg, Seoul National University Hospital,
Abstract
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, Cleveland Clinic Lerner College of Medicine, Princess Margaret Cancer Centre, Moffitt Cancer Center,
Abstract
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
Org: University College London Cancer Institute, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Manchester Royal Infirmary, Texas Transplant Physician Grp, PLLC,
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.
Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,
Abstract
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Org: National Taiwan University Hospital and National Taiwan University Cancer Center, Seoul National University Bundang Hospital, Istituto Europeo di Oncologia, Osaka International Cancer Institute, Osaka, Japan, Peking Union Medical College Hospital,
Abstract
Clonal hematopoiesis in survivors of childhood cancer.
Org: New York City, St Louis, Washington University School of Medicine, ModernaTX, St. Louis,
Abstract
Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141).
Org: Brown University School of Public Health, Brown University School of Medicine-Rhode Island Hospital, University of Washington School of Medicine, Memorial Sloan Kettering Cancer Center, University of Rochester,
Abstract
Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.
Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Disparities in outcomes among hospitalized unhoused patients with cancer in the US.
Org: NYU Grossman School of Medicine, Department of Radiation Oncology, Tufts University School of Medicine, Memorial Sloan Kettering Cancer Center, Washington University School of Medicine in St. Louis,
Abstract
Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.
Org: Memorial Sloan Kettering Cancer Center, Knight Cancer Institute, University of Iowa Carver College of Medicine, University of Michigan Rogel Comprehensive Cancer Center, Sarcoma Oncology Center,
Abstract
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,
Abstract
Reduced symptom burden after implementation of an electronic symptom management program.
Org: MaineHealth Cancer Care, Department of Medical Oncology, Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, WVU Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Differential burnout by race, sex, and sexual orientation in academic oncology.
Org: University of Utah, Memorial Sloan Kettering Cancer Center, University of California San Francisco, Association of American Medical Colleges,
Abstract
POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.
Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.
Org: The University of Texas MD Anderson Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, Baylor College of Medicine, University of Pennsylvania, Central Connecticut Radiation Oncology,
Abstract
Redefining early-onset cancer and risk of hereditary cancer predisposition.
Org: Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Sarcoma Medical Oncology Service,
Abstract
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.
Org: Vanderbilt University Cancer Center, University of Amsterdam, Stanford University School of Medicine, Washington University School of Medicine, Hematology Department, Institut Català d'Oncologia-Hospitalet,
Abstract
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.
Org: Memorial Sloan Kettering Cancer Center, Kanagawa Cancer Center, Severance Hospital, Hospital Clinic de Barcelona, Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.
Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.
Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Org: Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UT Southwestern Simmons Comprehensive Cancer Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Efficacy of eSyM: Acute care utilization among patients with cancer who do versus do not report ePROs.
Org: Dana-Farber Cancer Institute, MaineHealth Cancer Care, Lifespan Cancer Institute, WVU Cancer Institute, Baptist Cancer Center,
Abstract
Prescription drug monitoring program mandates and opioid prescriptions received by patients dying of cancer.
Org: Weill Cornell Medicine, University of Alabama at Birmingham, Albert Einstein College of Medicine, The University of Texas MD Anderson Cancer Center, Harvard Pilgrim Health Care Institute,
Abstract
Payor denial after prior authorization request for long-acting pain medication: Provider and patient perspectives.
Org: Memorial Sloan Kettering Cancer Center, University of Rochester, The University of North Carolina at Chapel Hill, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center,
Abstract
Implementing financial toxicity and health-related social risks screening and referral.
Org: School of Social Work, The University of North Carolina at Chapel Hill, Chapel Hill, NC, NYU Langone Health, Mineola, NY,
Abstract
State mandatory paid medical leave policies and cancer stage at diagnosis in US adults.
Org: Saint Louis University School of Medicine, Washington University School of Medicine in St. Louis, Memorial Sloan Kettering Cancer Center, American Cancer Society, Washington University School of Medicine,
Abstract
Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment.
Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.
Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
Org: Berry Consultants, LLC, Global Coalition for Adaptive Research, Hunstman Cancer Institute at the University of Utah, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.
Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,
Abstract
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.
Org: Memorial Sloan Kettering Cancer Center, Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, University of Cincinnati Cancer Center, START Midwest, Grand Rapids, MI,
Abstract
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Org: START Midwest, Grand Rapids, MI, Memorial Sloan Kettering Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Yale School of Medicine, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Fudan University Shanghai Cancer Center, University of California Irvine, the First Affiliated Hospital, Zhejiang, University School of Medicine, Shanghai Medical College, Fudan University,
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.
Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).
Org: Rush University Medical Center, NRG Oncology SDMC/ACR, Mount Sinai Medical Center, University of Maryland, Baltimore, MD, Brown University School of Medicine-Rhode Island Hospital,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).
Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Org: Bradford Hill Clinical Research Center, Erasmus MC Cancer Institute, Centre Georges-François Leclerc, Dijon, France, Arturo Lopez Perez Foundation Oncology Institute, Institut régional du Cancer de Montpellier (ICM),
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.
Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).
Org: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Baylor College of Medicine, Mayo Hosp, Memorial Sloan Kettering Cancer Center,
Abstract
Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for human papillomavirus-related oropharyngeal cancer.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Miami Cancer Institute, Miami, FL, Hartford Health Care,
Abstract
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
Org: Memorial Sloan Kettering Cancer Center, Medical University of Silesia, Hematology Ward, S. Eugenio Hospital, The University of Texas MD Anderson Cancer Center,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.
Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.
Org: Autolus Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, The David and Etta Jonas Center for Cellular Therapy, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).
Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).
Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Abstract
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.
Org: Roche Products Ltd., Genentech, Memorial Sloan Kettering Cancer Center, Hopp Children’s Cancer Center Heidelberg (KiTZ), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.
Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Radiation dose escalation and local control for intermediate-risk rhabdomyosarcoma on ARST1431: A report from the Children’s Oncology Group
Org: Memorial Sloan Kettering Cancer Center, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, The Hospital for Sick Children, Cincinnati Children's Hospital Medical Center, University of Pennsylvania,
Abstract
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.
Org: Dana-Farber Cancer Institute, Boston Children's Hospital Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Children's Mercy Hospital,
Abstract
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
Org: Memorial Sloan Kettering Cancer Center, Chris O'Brien Lifehouse, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Sarcoma Center, Dana-Farber Cancer Institute,
Abstract
SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).
Org: Children's Hospital of Philadelphia, Mayo Clinic, Department of Population Health Sciences, Weill Cornell Medicine, Children’s Hospital Los Angeles,
Abstract
Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.
Org: Memorial Sloan Kettering Cancer Center, Harvard Medical School, Weill Cornell Medicine, NYU Langone Health, Department of Pathology and Laboratory Medicine,
Abstract
A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.
Org: Memorial Sloan Kettering Cancer Center, Interventional Radiology Service,
Abstract
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Org: Yale University School of Medicine and Yale Cancer Center, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Johns Hopkins University, University of Pennsylvania Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center,
Abstract
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.
Org: University of Pittsburgh Medical Center Hillman Cancer Center, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Aichi Cancer Center Hospital, Memorial Sloan Kettering Cancer Center, University of Ulsan College of Medicine,
Abstract
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.
Org: Memorial Sloan Kettering Cancer Center, Duke University Medical Center, Vall d’Hebron University Hospital/VHIO, Institut Català d'Oncologia L´Hospitalet, Ramón y Cajal University Hospital,
Abstract
International medical graduates (IMG) representation at international oncology conference meetings.
Org: Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Gazi University Faculty of Medicine, University of Arkansas for Medical Sciences,
Abstract
Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.
Org: Sharei Zedek Hospital, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, Baptist Health South Florida,
Abstract
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.
Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,
Abstract
Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer.
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, Emory University at Winship Cancer Institute, Clinical Care Options, LLC,
Abstract
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).
Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Florida Cancer Specialists/Sarah Cannon Research Institute, University of Virginia, Charlottesville, VA, USA, Memorial Sloan Kettering Cancer Center,
Abstract
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.
Org: Memorial Sloan Kettering Cancer Center, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, Breast Service, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.
Org: Memorial Sloan Kettering Cancer Center, SUNY Downstate Medical Center, Lombardi Comprehensive Cancer Center, Georgetown University, Lombardi Comprehensive Cancer Center,
Abstract
Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.
Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine and Fred Hutchinson Cancer Center, University of Pittsburgh, Washington University School of Medicine, Kaplan Hospital,
Abstract
Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study.
Org: Memorial Sloan Kettering Cancer Center, Kaiser Permanente Washington Health Research Institute, Rogel Cancer Center, University of Michigan, The Permanente Medical Group Consulting Services, Kaiser Permanente Division of Research,
Abstract
Effects of plant-based diet (PBD) and exercise therapy (Ex) on weight and body composition in patients with primary hormone receptor (HR) positive breast cancer: A phase 2 randomized controlled trial.
Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham,
Abstract
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.
Org: Dana-Farber Cancer Institute, 4D Path Inc., Vanderbilt University Medical Center, University of Pittsburgh, O'Neal Comprehensive Cancer Center at UAB,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).
Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Instituto Valenciano de Oncología,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, Women and Infants Hospital of Rhode Island,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.
Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
Evaluation of the study of control arms in randomized clinical trials of cancer.
Org: Brown University School of Medicine-Rhode Island Hospital, Memorial Sloan Kettering Cancer Center, Yale University School of Medicine, Saint Louis University School of Medicine, UNC Lineberger Comprehensive Cancer Center,
Abstract
Cancer care service use intensity in Medicare Advantage versus traditional Medicare.
Org: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center, McDermott+ Consulting, University of Minnesota, George Mason University, Manassas, VA,
Abstract
Overlapping and non-overlapping indications for checkpoint inhibitors in the US.
Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Trends in pharmaceutical industry payments to US cancer centers, 2014-2021.
Org: Memorial Sloan Kettering Cancer Center, US Digital Corps, US General Services Administration, DELFI Diagnostics, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Trends in NCCN enforcement of financial conflict of interest policies for guidelines panelists.
Org: Memorial Sloan Kettering Cancer Center, DELFI Diagnostics, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Yale University School of Medicine, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Cost trends in standard-of-care cancer treatments, 2017-2021.
Org: New York Presbyterian/Weill Cornell Medical Center, Memorial Sloan Kettering Cancer Center, University of Chicago, Harris School of Public Policy, Yale University School of Medicine, DELFI Diagnostics,
Abstract
Trends in prices of checkpoint inhibitors in the US, 2016-2023.
Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Effect of multi-cancer early detection screening on late-stage cancers: A modeling study.
Org: Value Analytics Labs, LLC, Exact Sciences Corporation, Memorial Sloan Kettering Cancer Center, Medical University of South Carolina, London School of Hygiene & Tropical Medicine,
Abstract
Performance of a trained large language model to provide clinical trial recommendation in a head and neck cancer population.
Org: Memorial Sloan Kettering Cancer Center, Columbia University, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).
Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Center for Head and Neck Cancers, Massachusetts General Hospital, Medical Oncology Department. Vall Hebron University Hospital,
Abstract
Importance of information-seeking styles among patients with cancer pre- and post-treatment: A URCC NCORP Research Base study.
Org: University of Rocheser Medical Center, Rochester, NY, James P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester,
Abstract
Identifying modifiable risk factors to improve immigrant breast cancer screening in the United States.
Org: Memorial Sloan Kettering Cancer Center, Washington University School of Medicine in St. Louis, NYU Grossman School of Medicine, American Cancer Society,
Abstract
The influence of access to care on radiation therapy utilization among older women with breast cancer.
Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Institute for Healthcare Delivery Science, Tisch Cancer Institute, Department of Population Health Science and Policy, Memorial Sloan Kettering Cancer Center,
Abstract
The acceptability of hospital-at-home for persons living with cancer and their caregivers.
Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center,
Abstract
Trends in location of death for individuals with pediatric cancer in the United States.
Org: University of Pittsburgh, Yale College, Stanford School of Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, NYC Health + Hospitals/Elmhurst,
Abstract
Patient satisfaction with cancer care delivery through telemedicine at a comprehensive cancer center across three years during and after the COVID-19 pandemic.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Patient-reported experience with an immunotherapy telehealth platform.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases.
Org: Brown University School of Medicine-Rhode Island Hospital, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Albert Einstein College of Medicine,
Clinical trial
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Genomic Profiling in Cancer Patients
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors
Status: Recruiting, Estimated PCD: 2028-05-04
Clinical trial
Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of HB-200 in Patients With Positive TTMV-HPV DNA After Definitive Treatment for HPV16 Positive HNSCC
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia
Status: Active (not recruiting), Estimated PCD: 2025-02-23
Clinical trial
Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma
Status: Completed, Estimated PCD: 2023-12-06
Clinical trial
A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage Repair
Status: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase I Study of the Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Abstract
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.
Org: Roche Products Ltd., Genentech, Roche Products Limited, German Breast Group, Centre for Haematology and Oncology Bethanien,
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.
Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Shareable artificial intelligence to extract cancer outcomes from electronic health records.
Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Dana-Farber Cancer Institute, Boston, MA, USA, Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Dana-Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute,
Abstract
High deductible health plans and survival among cancer survivors.
Org: Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Costs of Care, Boston, University of Minnesota Masonic Cancer Center, University of California, San Francisco,
Abstract
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.
Org: Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Department of Medical Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, Cancer Convergence Institute, Bloomberg-Kimmel Institute, Baltimore, MD, Ontario Institute for Cancer Research, Toronto, ON, Canada, Northwell Health Cancer Institute, Lake Success, NY, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD,
Abstract
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Org: Euromed service, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, The University of Texas MD Anderson Cancer Center, British Columbia Cancer Agency, Asan Medical Center,
Abstract
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).
Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,
Abstract
CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.
Org: Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Repare Therapeutics, Saint-Laurent, QC, Canada, Repare Therapeutics, Cambridge, MA, University of Milan and European Institute of Oncology, IRCCS, Milan, Italy,
Abstract
Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd).
Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NYU Grossman Long Island School of Medicine, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.
Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Clinical trial
A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma
Status: Recruiting, Estimated PCD: 2027-06-09
Clinical trial
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract (Including Ureter and Renal Pelvis)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase 2 Trial of Ulixertinib for Patients With Histiocytic Neoplasms
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-20
Clinical trial
Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Status: Completed, Estimated PCD: 2023-01-11
Clinical trial
An Open-Label, Pilot Study of Romiplostim for Conditioning Regimen-Related Thrombocytopenia After High-Dose Therapy and Autologous Hematopoietic Cell Transplantation
Status: Completed, Estimated PCD: 2023-06-08
Clinical trial
Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody
Status: Recruiting, Estimated PCD: 2026-06-11
Clinical trial
Phase II Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients With Myeloid Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Status: Completed, Estimated PCD: 2023-11-07
Clinical trial
Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Status: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Cluster-Randomized, Prospective Assessment of Postoperative Pain Management in Patients Undergoing Bilateral Mastectomy With Immediate Reconstruction With Tissue Expander (BMWRw/TE) Using Preoperative Paravertebral (PVB), Serratus+PECS-1, or PVB+PECS-1 Nerve Blocks
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Status: Completed, Estimated PCD: 2024-04-03
Clinical trial
A Phase 1 Study of Pembrolizumab Plus Cryoablation in Patients With Unresectable Mesotheliomas
Status: Completed, Estimated PCD: 2023-12-18
Clinical trial
Phase 2 Study of Personalized r-ATG Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (PRAISE-IR)
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer
Status: Completed, Estimated PCD: 2003-05-01
Clinical trial
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Pilot Study of Radiation De-Escalation for p16 Negative Oropharyngeal Cancer and p16-Negative or Positive Laryngeal and Hypopharyngeal Cancers
Status: Recruiting, Estimated PCD: 2027-03-12
Clinical trial
A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy as Consolidation and Maintenance Therapy for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging In Patients Advanced Breast Cancer
Status: Withdrawn, Estimated PCD: 2024-04-29
Clinical trial
A Phase II Study of Nivolumab in Combination With FOLFOX and Regorafenib in Patients With HER2-Negative Metastatic Esophagogastric Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL "Armored" Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Randomization of Oral β-glucan, for High-Risk Neuroblastoma
Status: Recruiting, Estimated PCD: 2026-03-21
Clinical trial
A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor
Status: Recruiting, Estimated PCD: 2025-03-02
Clinical trial
A Phase II Study of Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab Refractory Advanced Esophagogastric Cancer
Status: Completed, Estimated PCD: 2023-02-20
Clinical trial
Phase II Maintenance Trial of Nivolumab for Newly Diagnosed PCNSL Patients With Persistent Circulating Tumor DNA in the CSF After Completion of Methotrexate-Based First-Line Induction Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2026-05-22
Abstract
Combined impact of primary tumor molecular profile and location in the relapse pattern of early-stage, microsatellite stable colorectal cancer.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).
Org: Memorial Sloan Kettering Cancer Center,
Abstract
A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types.
Org: Memorial Sloan Kettering Cancer Center, AstraZeneca, Early Drug Development Group,
Abstract
Utilization patterns and outcomes of radiotherapy for patients with germ cell tumor relapsing with brain metastases, with a focus on stereotactic radiosurgery.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Foundation Medicine, Inc., Cambridge, MA,
Abstract
Induction chemotherapy effects on very advanced (T3/T4) human papillomavirus-related oropharyngeal cancer for participation in hypoxia-directed major de-escalation (30 Gy) definitive treatment trial.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Does non-alcoholic fatty liver disease increase the risk for pancreatic cancer? A multi-center retrospective cohort study.
Org: University of Illinois College of Medicine Peoria (UICOMP), Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center,
Abstract
A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.
Org: Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO).
Org: Memorial Sloan Kettering Cancer Center, Adaptive Phage Therapeutics, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
MRI compared to 123I-MIBG scan for detection of central nervous system relapse in neuroblastoma.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort.
Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
Org: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Jilin Cancer Hospital, Taiho Oncology Inc.,
Abstract
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).
Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Jilin Cancer Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Hospital Universitario 12 de Octubre,
Abstract
Randomized  PROSTATE-IQ trial to reduce ADT treatment burden for patients with biochemical recurrence after prostatectomy.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).
Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Memorial Sloan Kettering Cancer Center,
Abstract
Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Safety and immunological effects of ablative radiotherapy followed by pembrolizumab in patients with advanced adrenocortical carcinoma.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology & Biostatistics,
Abstract
Timeliness of breast cancer care: Real-world experience at a tertiary care and a public safety-net hospital.
Org: Olive View-UCLA Medical Center, University of California Irvine, Memorial Sloan Kettering Cancer Center,
Abstract
Enhancing thoracic oncology in Armenia: Impact of the implementation of an expert-guided virtual multidisciplinary tumor board.
Org: Yeolyan Hematology and Oncology Center, Department of Pediatric Oncology and Hematology, Immune Oncology Research Institute, Yerevan State Medical University after M. Heratsi, Memorial Sloan Kettering Cancer Center,
Abstract
Combining a WT1 cancer vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma (DPM): A phase I study.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).
Org: James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT).
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Correlation of allele-specific HLA loss of heterozygosity in patients with cancer with driver mutations.
Org: Affini-T Therapeutics, Inc., Foundation Medicine, Inc., Cambridge, MA, Memorial Sloan Kettering Cancer Center,
Abstract
Combined modality for localized gastric diffuse large B-cell lymphoma: Long-term outcomes of 50 patients.
Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
The combination of patient-specific tumor and HPV sequencing to enable high-sensitivity detection of ctDNA in patients with HPV-associated oropharyngeal carcinoma.
Org: Memorial Sloan Kettering Cancer Center, Invitae, Invitae Corporation, AstraZeneca,
Abstract
Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED.
Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University College London Cancer Institute, South Australian Immunogenomics Cancer Institute, University of Adelaide,
Abstract
Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center,
Abstract
Financial toxicity and unmet essential needs in patients with gastrointestinal cancer.
Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,
Abstract
Signatures of early plasticity in the histological transformation of lung cancer.
Org: Columbia University Vagelos College of Physicians and Surgeons, Memorial Sloan Kettering Cancer Center,
Abstract
ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC).
Org: Carolina Urologic Research Center and GenesisCare US, Steba/Impact Biotech, Weizmann Institute of Science, Memorial Sloan Kettering Cancer Center,
Abstract
Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
Org: Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Queen Mary University of London, Genitourinary Oncology Service, Weill Cornell Medical College University,
Clinical trial
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
Status: Recruiting, Estimated PCD: 2025-11-01
Abstract
Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (GCT) receiving palliative chemotherapy in the United States.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, BioNTech, New Kensignton, PA, Analysis Group, Inc.,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.
Org: Mayo Clinic Comprehensive Cancer Center, IRCCS San Raffaele Hospital, UCL Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
Evaluating antitumor activity and response determinants to trastuzumab deruxtecan in pediatric solid tumors.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma.
Org: Stanford Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,
Abstract
Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).
Org: Memorial Sloan Kettering Cancer Center, Seres Therapeutics, University of Chicago, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic,
Abstract
A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.
Org: Stanford University School of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC.
Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Center for Molecular Oncology,
Abstract
Tracking the FDA precision oncology drug approval landscape in OncoKB.
Org: Memorial Sloan Kettering Cancer Center, Center for Molecular Oncology, Department of Pathology and Laboratory Medicine,
Abstract
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.
Org: UT Southwestern Medical Center, Dallas, City of Hope National Comprehensive Cancer Center, Duarte, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Use of an application that extracts and consolidates adverse events and concomitant medication data from clinical systems to increase clinical trial data entry efficiency, trust, and satisfaction.
Org: Memorial Sloan Kettering Cancer Center,
Clinical trial
A Prospective Single Arm Non-inferiority Trial of Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma (Major De-escalation to 30Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma)
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Abstract
Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.
Org: Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.
Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,
Clinical trial
A Pilot Study of Oral Minoxidil for the Treatment of Persistent Hair Loss in Pediatric, Adolescent, and Young Adult Cancer Survivors
Status: Recruiting, Estimated PCD: 2026-03-01
Abstract
Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial.
Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Racial and ethnic differences in patient-reported provider communication among patients with cancer.
Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Memorial Sloan Kettering Cancer Center,
Abstract
A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment (ACT).
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.
Org: Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Pennsylvania, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).
Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Children's Oncology Group Statistics and Data Center, University of Florida, Broad Institute of MIT and Harvard, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center,
Abstract
MSK Engage: A comprehensive program for collection of patient reported outcomes at scale.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.
Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center,
Abstract
Patient-reported experiences with cannabidiol (CBD) after cancer diagnosis.
Org: Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer.
Org: Memorial Sloan Kettering Cancer Center, New York City, Nykode Therapeutics, New York Oncology Hematology PC, Columbia University Vagelos College of Physicians and Surgeons,
Abstract
­­­­­­Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.
Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
Improving chemotherapy-induced alopecia for women receiving anthracycline plus taxane chemotherapy using the Paxman scalp cooling system at lower temperatures.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Dermatology Service, NYU Langone Health, New York, NY,
Abstract
Immune-related adverse event prediction and influential factor identification.
Org: Georgetown University Medical Center, Washington, DC, Georgetown Lombardi Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
Org: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori,
Abstract
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.
Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.
Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for International Blood and Marrow Transplant Research,
Abstract
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Institut Gustave Roussy, Villejuif, France, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan,
Abstract
Sexual health outcomes in sexual minority vs. heterosexual men after prostate radiotherapy.
Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, Medical College of Wisconsin, Division of Infectious Diseases,
Clinical trial
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Abstract
Optimizing clinical research in a regional cancer center network: A survey-based approach.
Org: Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Predicting fitness for chemotherapy in older adults with metastatic bladder cancer.
Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Memorial Sloan Kettering Cancer Center,
Abstract
Retrieval-augmented large language models for clinical trial screening.
Org: Memorial Sloan Kettering Cancer Center, National University of Singapore, National Cancer Centre Singapore, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Body mass index (BMI) as a prelude to hepatocellular carcinoma (HCC) and metabolic dysfunction–associated steatohepatitis (MASH) risk factors in patients with no identified risk factor for developing hepatocellular carcinoma (HCC).
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology & Biostatistics, Weill Cornell Medical College University, Weill Medical College at Cornell University,
Clinical trial
A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Abstract
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, University of Michigan,
Abstract
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,
Clinical trial
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Status: Completed, Estimated PCD: 2022-12-19
Abstract
Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer.
Org: Memorial Sloan Kettering Cancer Center, Kaiser Permanente Washington Health Research Institute, Rogel Cancer Center, University of Michigan, The Permanente Medical Group Consulting Services, Kaiser Permanente Division of Research,
Clinical trial
A Phase I/II Study of Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Status: Completed, Estimated PCD: 2024-03-21
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Clinical trial
Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Abstract
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.
Org: Samsung Medical Centre, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Memorial Sloan Kettering Cancer Center,
Abstract
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.
Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,
Clinical trial
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2027-06-01
Abstract
Quality of life in patients with malignant wounds treated at a wound care clinic.
Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC,
Clinical trial
Double Blind, Randomized, Placebo Controlled Trial of Locally Instilled Bupivacaine in the Surgical Bed After Unilateral Mastectomy Without Reconstruction
Status: Recruiting, Estimated PCD: 2026-11-01
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).
Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Clinical trial
Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-08
Clinical trial
Phase 2 Study of Tafasitamab and Lenalidomide in Relapsed or Refractory Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-03-14
Clinical trial
A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-01-10
Abstract
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.
Org: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center, Boston, MA,
Clinical trial
SAABR: Single Arm Phase II Study of AR Targeted Therapy + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Abstract
A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.
Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Characterizing TP53 mutations in bone and soft tissue sarcoma.
Org: Memorial Sloan Kettering Cancer Center, Fellowship (GME Office), Sarcoma Medical Oncology Service,
Abstract
Diagnosis disclosure patterns among patients with plasma cell disorders.
Org: Geisel School of Medicine at Dartmouth, University of Illinois Chicago, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center, HealthTree Foundation,
Clinical trial
A Feasibility Study of Flibanserin in Breast Cancer Survivors on Tamoxifen and Aromatase Inhibitors
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Phase I Study Evaluating the Safety and Tolerability of Locally Administered Anti-CD40 Agonist Antibody (2141-V11) in Subjects With Bladder Cancer
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma
Status: Recruiting, Estimated PCD: 2025-06-22
Clinical trial
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
Maximal Ablative Irradiation Because of Encasement (MAIBE) for Patients With Potentially Resectable Locally Advanced Pancreatic Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Phase 1b / 2a, Open-label Platform Study to Evaluate Mirdametinib as Monotherapy or in Combination With Other Anticancer Agents in Patients With Advanced Solid Cancers Harboring MAPK-activating Mutations
Status: Completed, Estimated PCD: 2023-10-26
Clinical trial
A Phase I Study Assessing the Safety and Tolerability of Ascending Doses of AZD1390 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2028-05-17
Clinical trial
Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium
Status: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers
Status: Completed, Estimated PCD: 2022-03-01
Clinical trial
SAXON-PC: A Phase II Randomized Trial of Stereotactic Body Radiation Therapy (SBRT) And Radium (Ra-223) Dichloride for Oligorecurrent, Non-castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-11-12
Clinical trial
A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas
Status: Completed, Estimated PCD: 2021-08-03
Clinical trial
A Phase II, Multicenter, Single-Arm Clinical Trial of Radiotherapy and CeMiPlimAb: Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Status: Recruiting, Estimated PCD: 2026-10-06
Clinical trial
Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
Fecal Microbiota Transplantation (FMT) for Immune Checkpoint Inhibitor (ICI)-Related Diarrhea: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Status: Completed, Estimated PCD: 2024-04-01
Clinical trial
Phase I/II Study of Transarterial Hepatic Embolization With Bumetanide in Unresectable Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-04-05
Clinical trial
A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma
Status: Recruiting, Estimated PCD: 2027-05-23
Clinical trial
A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC
Status: Recruiting, Estimated PCD: 2025-12-09
Clinical trial
A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status: Completed, Estimated PCD: 2024-02-22
Clinical trial
Phase II Study Evaluating the Effects of Single Site Intratumoral Injections of Anti-CD40 Agonist Antibody (2141-V11) Given as Monotherapy Prior to Radical Prostatectomy to Men With Intermediate Risk Disease and in Combination With Androgen Deprivation Therapy for Those With High Risk Localized and Low Volume Metastatic Disease
Status: Recruiting, Estimated PCD: 2029-03-28
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2024-01-22
Clinical trial
A Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Phase Ib Trial With Dose Expansion of the Bruton"s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance
Status: Recruiting, Estimated PCD: 2028-05-09
Clinical trial
A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER
Status: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Completed, Estimated PCD: 2023-11-13
Clinical trial
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2024-03-14
Clinical trial
A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Sulfonylurea Safety and Effectiveness (SUSS) for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Revie
Status: Recruiting, Estimated PCD: 2025-12-05
Clinical trial
A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Single Arm Open-Label Pilot Study of Prophylactic Romiplostim Use Compared to Benchmark Rate in the Prevention of Chemotherapy Induced Thrombocytopenia in Pediatric Solid Tumors Patients Undergoing Myelosuppressive Chemotherapy
Status: Terminated, Estimated PCD: 2023-03-29
Clinical trial
Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
Status: Active (not recruiting), Estimated PCD: 2027-07-01
Clinical trial
Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
Status: Completed, Estimated PCD: 2023-02-02
Clinical trial
Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer With Homologous Recombination Deficiency (PreCISeRT)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Phase I Trial of Real-Time Intraoperative Fluorescent Imaging of Nerve Structures Using Illuminare-1, A Novel Myelin-Binding Fluorophore
Status: Recruiting, Estimated PCD: 2025-10-04
Clinical trial
A Phase II Trial of Xevinapant in Combination With Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-11
Clinical trial
A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders
Status: Completed, Estimated PCD: 2022-12-16
Clinical trial
RETENTION: An Open-Label Phase 2 Trial of InteRlEukin (5) InhibiTion for the prEveNTION of Alpelisib Rash in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2023-02-06
Clinical trial
Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
CHARIOT: A Phase 1b/2 Study of Androgen Deprivation Therapy and Copanlisib in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma
Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Molecular Phenotyping and Image-Guided Surgical Treatment of Prostate Cancer Using Ultrasmall Silica Nanoparticles
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
Phase II Trial of Short Course Androgen Deprivation, Hypofractionated Pelvic Radiation and a Brachytherapy Boost for NCCN High-Risk Prostate Cancer With Low-Intermediate Risk Decipher Genomic Score
Status: Active (not recruiting), Estimated PCD: 2025-10-19
Clinical trial
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
Status: Active (not recruiting), Estimated PCD: 2025-02-07
Clinical trial
Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized Controlled Trial of the Soluble Guanylate Cyclase Stimulator Vericiguat in Patients With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction (ELEVATE)
Status: Recruiting, Estimated PCD: 2028-07-17
Clinical trial
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Status: Completed, Estimated PCD: 2020-12-18
Clinical trial
Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell Lymphomas
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-02
Clinical trial
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab With Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
Status: Recruiting, Estimated PCD: 2027-11-30
Clinical trial
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-06-20
Clinical trial
A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Status: Recruiting, Estimated PCD: 2025-10-21
Clinical trial
A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
BV-AVD in Patients With Newly-Diagnosed, Early Stage, Bulky Hodgkin Lymphoma Using a PET-adapted and MTV-guided Approach
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
PSMA PET Imaging of Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
Status: Completed, Estimated PCD: 2023-09-25
Clinical trial
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Serial PSMA PET Imaging in the Assessment of Treatment Response in Patients With Progressive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Jet-Injection Assisted Photodynamic Therapy for Basal Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-09-09
Clinical trial
Phase Ib/II Study of Induction Chemotherapy and Durvalumab (MEDI4736) and Tremelimumab With Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-03-16
Clinical trial
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer at Moderate to High Risk of Recurrence
Status: Terminated, Estimated PCD: 2023-03-02
Clinical trial
A Phase 1 Study of Concurrent Cabozantinib and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Safety of Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2024-02-16
Clinical trial
Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?
Status: Recruiting, Estimated PCD: 2027-01-29
Clinical trial
Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Venetoclax in Combination With Asparaginase-Containing Pediatric-Inspired Chemotherapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 1b Multi-center Study of the FLT3 Inhibitor Gilteritinib in Combination With the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-occurring FLT3/IDH1 or FLT3/IDH2 Mutations
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase I Study of Pretargeted PET Imaging Using 64Cu-Tz-SarAr and a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO) in Patients With Pancreatic, Bladder Cancer, Gastrointestinal Malignancies or Solid Tumors With Elevated CA19-9
Status: Recruiting, Estimated PCD: 2025-02-10
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination With Rituximab in Subjects With Treatment Naïve Marginal Zone Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Single-Arm Pilot Study of Adjuvant Pembrolizumab in Patients With MSI-H Tumors With Persistent Circulating Tumor DNA Following Surgery
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase 1 Study of Combination Dacomitinib and Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase I/II Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer
Status: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Status: Active (not recruiting), Estimated PCD: 2027-05-01
Clinical trial
A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer
Status: Completed, Estimated PCD: 2024-06-07
Clinical trial
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)
Status: Recruiting, Estimated PCD: 2027-09-22
Clinical trial
Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Opioid-Sparing Pain Treatment In Myeloma And Lymphoma Patients Undergoing High-Dose Chemotherapy (OPTIMAL-HiChemo): Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Pilot Study of 89Zr-DFO-REGN3767 Anti LAG-3 Antibody Positron Emission Tomography in Patients With Relapsed/Refractory DLBCL
Status: Active (not recruiting), Estimated PCD: 2025-09-11
Clinical trial
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2025-02-14
Clinical trial
RP-3500 (ATRi) + External Beam Radiotherapy (EBRT) for the Palliative Treatment of Metastatic Disease
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)
Status: Active (not recruiting), Estimated PCD: 2024-11-19
Clinical trial
A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas
Status: Recruiting, Estimated PCD: 2024-12-23
Clinical trial
A Phase 1a/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-10-13
Clinical trial
Phase II Combination of 131I-Omburtamab Radioimmunotherapy and External Beam Radiotherapy for Desmoplastic Small Round Cell Tumor
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-04-06
Clinical trial
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Immuno-Positron Emission Tomography, Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
Status: Recruiting, Estimated PCD: 2030-03-04
Clinical trial
A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers
Status: Completed, Estimated PCD: 2023-09-29
Clinical trial
A Randomized, Double-Blind, Controlled Trial of Combined Amiodarone and N-Acetylcysteine Versus Amiodarone Plus Placebo for the Prevention of Atrial Fibrillation in High Risk Patients Undergoing Thoracic Surgery
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Status: Completed, Estimated PCD: 2008-06-01
Clinical trial
Modulation of Post-operative Opioid Consumption and Pain by Intraoperative Methadone for Cancer Related Spinal Surgery - An Investigator Initiated Trial (IIT), Cluster Randomization Trial
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-06-20
Clinical trial
Phase II Study of Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle- Invasive Bladder Cancer (NMIBC) and High- Grade Non-Muscle- Invasive Upper Tract Urothelial Cell Carcinoma (NMI-UTUCC)
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2022-08-02
Clinical trial
Safety and Immunological Effects of Ablative Radiotherapy Followed by Pembrolizumab in Patients With Advanced Adrenocortical Carcinoma
Status: Recruiting, Estimated PCD: 2026-09-27
Clinical trial
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase II Single-Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy With Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-01-22
Clinical trial
An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)
Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
Status: Completed, Estimated PCD: 2023-08-02
Clinical trial
Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Oral β-glucan and Randomization of GM-CSF, for High-risk Neuroblastoma
Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Status: Completed, Estimated PCD: 2008-06-01
Clinical trial
Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase I/II Study of Binimetinib With Encorafenib in Patients With Non-V600 Activating BRAF Mutant Advanced Malignancies
Status: Completed, Estimated PCD: 2023-09-02
Clinical trial
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Phase I/Ib Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (DOSE SELECTION)
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Randomized Trial of Early, Upfront Palliative Radiation Therapy Versus Standard of Care for Patients With Highest Risk Asymptomatic or Minimally Symptomatic Bone Metastases
Status: Completed, Estimated PCD: 2024-04-18
Clinical trial
A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2022-02-04
Clinical trial
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Lenalidomide Maintenance in Plasma Cell Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Status: Completed, Estimated PCD: 2016-03-17
Clinical trial
89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging in Pancreatic Cancer or Other CA19-9 Positive Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease: A Pilot Chemoprevention Trial
Status: Completed, Estimated PCD: 2003-07-01
Clinical trial
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Status: Completed, Estimated PCD: 2016-05-19
Clinical trial
Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2022-02-02
Clinical trial
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Phase 1/2 Study of TPX-0005 (Repotrectinib) in Combination With Chemotherapy in Pediatric and Young Adult Subjects With Advanced or Metastatic Solid Tumors and Primary Central Nervous System Tumors
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Status: Completed, Estimated PCD: 2024-04-12
Clinical trial
A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection
Status: Completed, Estimated PCD: 2023-11-20
Clinical trial
Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy
Status: Completed, Estimated PCD: 2024-05-07
Clinical trial
A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer
Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery
Status: Completed, Estimated PCD: 2022-03-03
Clinical trial
A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase I, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-01-31
Clinical trial
Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Status: Completed, Estimated PCD: 2022-03-23
Clinical trial
Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Status: Terminated, Estimated PCD: 2024-03-06
Clinical trial
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Status: Completed, Estimated PCD: 2024-04-29
Clinical trial
Pilot Trial of Lifileucel (LN-144) for Patients With Asymptomatic Melanoma Brain Metastases and Progression on Prior PD1 Therapy
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Recruiting, Estimated PCD: 2028-05-22
Clinical trial
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Completed, Estimated PCD: 2022-02-24
Clinical trial
A Randomized Phase II Study of Sotorasib Versus Continued Consolidation Durvalumab in Patients With KRAS G12C Mutant Locally Advanced Non-small Cell Lung Cancer (LANSCLC) With Persistent ctDNA Defined Minimal Residual Disease
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Double-Masked Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery
Status: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3
Status: Completed, Estimated PCD: 2023-05-03
Clinical trial
An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status: Terminated, Estimated PCD: 2023-05-26
Clinical trial
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Multi-Center Phase I Dose Escalation Study of Avutometinib, a RAF/MEK Clamp, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway Alterations
Status: Recruiting, Estimated PCD: 2029-10-20
Clinical trial
Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2026-06-29
Clinical trial
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Randomized Trial of Modifications to Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-24
Clinical trial
Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Expanded Access Use of 131I-Omburtamab Intraventricular Radioimmunotherapy for Central Nervous System/Leptomeningeal Neoplasms
Status:
Clinical trial
Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors
Status: Completed, Estimated PCD: 2023-01-13
Clinical trial
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
Status: Recruiting, Estimated PCD: 2025-12-20
Clinical trial
Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Status: Completed, Estimated PCD: 2024-05-08
Clinical trial
A Phase I Study With Expansion Cohort of Concurrent GDC-0084 With Radiation Therapy for Patients With Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Status: Completed, Estimated PCD: 2023-10-01
Clinical trial
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
Status: Completed, Estimated PCD: 2024-05-13
Clinical trial
Rapid Motion-Robust Quantitative DCE-MRI For The Assessment Of Gynecologic Cancer
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2028-02-23
Clinical trial
A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Optimized In-Human [13C]Pyruvate MRI For Assessment Of Physiologic Reference Data In Different Organs
Status: , Estimated PCD: 2025-09-01
Clinical trial
Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer
Status: Completed, Estimated PCD: 2023-08-16
Clinical trial
A Phase I Study of T-cell Receptor Alpha Constant (TRAC) Locus Integrated CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With CD19+ Relapsed or Refractory Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-02-23
Clinical trial
A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)
Status: Completed, Estimated PCD: 2024-03-08
Clinical trial
A Pilot Protocol Evaluating Safety of Using the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in Patients With Colorectal Carcinoma or Cholangiocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors
Status: Completed, Estimated PCD: 2023-04-10
Clinical trial
A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Timing of Rectal Cancer Response to Chemoradiation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes
Status: Completed, Estimated PCD: 2023-01-05
Clinical trial
A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Status: Completed, Estimated PCD: 2024-03-05
Clinical trial
Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase I/II Study of DS-3201b, an EZH1/2 Inhibitor, in Combination With Irinotecan in Patients With Recurrent Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-05-02
Clinical trial
A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients With Glioma
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib.
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Randomized Phase II Double-Blinded Study of The Efficacy of Oleogel-S10 (AP101) Gel for the Treatment of Grade 2/3 Radiation Dermatitis in Breast Cancer Patients
Status: Recruiting, Estimated PCD: 2026-12-15
Clinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-02
Clinical trial
A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers
Status: Recruiting, Estimated PCD: 2028-08-17
Clinical trial
Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized Controlled Trial of Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Safety, Biodistribution and Radiation Dosimetry of [18F]PARPi
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase I/II Study of Gemcitabine and Docetaxel Combined With Immune Checkpoint Blockade (Retifanlimab) in Patients With Advanced Soft Tissue Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-09-29
Clinical trial
"A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study
Status: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Status: Completed, Estimated PCD: 2008-12-01
Clinical trial
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Pilot Study of Stereotactic Body Radiotherapy (SBRT) and 177Lu-PSMA-617 for the Treatment of Hormone Sensitive, Oligometastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Tibetree Pain-Relieving Plaster for Musculoskeletal Pain Among Cancer Survivors
Status: Active (not recruiting), Estimated PCD: 2024-05-28
Clinical trial
Romiplostim for Prevention of Severe Chemotherapy Induced Thrombocytopenia in Lymphoma Patients - Phase II Study
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib
Status: Recruiting, Estimated PCD: 2024-06-20
Clinical trial
A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy
Status: Active (not recruiting), Estimated PCD: 2024-08-28
Clinical trial
Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia
Status: Recruiting, Estimated PCD: 2029-05-21
Clinical trial
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 2 Study of Colesevelam for Lenalidomide-Associated Diarrhea
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma
Status: Active (not recruiting), Estimated PCD: 2024-11-05
Clinical trial
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER
Status: Withdrawn, Estimated PCD: 2023-04-25
Clinical trial
Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Completed, Estimated PCD: 2022-02-28
Clinical trial
A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
Status: Recruiting, Estimated PCD: 2029-08-01
Clinical trial
A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Enfortumab Vedotin in Combination With Pembrolizumab for Locally Advanced and/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study
Status: Recruiting, Estimated PCD: 2025-06-17
Clinical trial
A Phase 2 "Window of Opportunity" Trial of Targeted Therapy With Erdafitinib in Patients With Recurrent FGFR3-Altered Non-Muscle Invasive Bladder Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair
Status: Terminated, Estimated PCD: 2023-07-06
Clinical trial
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
Pilot Study of Glofitamab and Lenalidomide in Patients With Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With a BTK Inhibitor
Status: Recruiting, Estimated PCD: 2028-01-08
Clinical trial
A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma
Status: Terminated, Estimated PCD: 2023-06-05
Clinical trial
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Pilot Study of Lenvatinib Plus Pembrolizumab in Patients With Advanced Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Pilot Study Investigating Intrahepatic Arterial And Intravenous Infusion Of The Radiolabeled Somatostatin Agonist 177Lu-DOTATATE In Patients With Liver-Dominant Metastatic Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Well Differentiated Neuroendocrine Tumors
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients
Status: Withdrawn, Estimated PCD: 2023-02-15
Clinical trial
Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Status: Active (not recruiting), Estimated PCD: 2019-01-11
Clinical trial
A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
Status: Terminated, Estimated PCD: 2022-10-28
Clinical trial
Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Abstract
Identifying clinical trial candidates using AI predictions of treatment change: A pilot implementation study.
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS).
Org: Memorial Sloan Kettering Cancer Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).
Org: Memorial Sloan Kettering Cancer Center, Hartford Health Center Cancer Institute, Lehigh Valley Topper Cancer Institute, Weill Cornell Medical College University,
Abstract
Fertility post immune checkpoint blockade.
Org: Memorial Sloan Kettering Cancer Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Netherlands Cancer Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Org: Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, UPMC Hillman Cancer Center, Abramson Cancer Center, Karmanos Cancer Institute,
Abstract
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), University of Virginia, Charlottesville, VA, USA, University Hospitals Leuven, Leuven, Belgium, Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Org: Moffitt Cancer Center, Stanford Cancer Center, Washington University School of Medicine in St Louis, University of Washington and Fred Hutchinson Cancer Research Centre, Massachusetts General Hospital,
Abstract
Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).
Org: Memorial Sloan Kettering Cancer Center,
Abstract
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,
Abstract
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.
Org: Mayo Clinic, University Hospitals Gasthuisberg Leuven, KU Leuven, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Abstract
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Org: Memorial Sloan Kettering Cancer Center, Guy’s and St Thomas’ NHS Trust, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia "Seràgnoli", Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
Org: Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCI Health,
Abstract
Neoplasia detection via colonoscopic surveillance among young patients with MSH6 and PMS2-associated Lynch syndrome.
Org: Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Dana-Farber Cancer Institute, University of Pennsylvania Perelman School of Medicine,
Abstract
Big data in oncology: Challenges and solutions.
Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Genitourinary Oncology Service, Thoracic Oncology Service,
Abstract
Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.
Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Sutter Health, Intermountain Healthcare, Mayo Clinic,
Abstract
Workplace sexual harassment in academic oncology.
Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Middletown, Association of American Medical Colleges, Alexandria, VA,
Abstract
A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC).
Org: Memorial Sloan Kettering Cancer Center, University of Texas Southwestern Medical Center, Weizmann Institute of Science, Steba Biotech, Impact Biotech,
Abstract
The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer.
Org: Breast Service, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Biostatistics Service,
Abstract
Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.
Org: University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Dana-Farber Cancer Institute,
Abstract
A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
Org: Memorial Sloan Kettering Cancer Center, University of Chicago, Mayo Clinic, Massachusetts General Hospital, Seres Therapeutics,
Abstract
Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.
Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering - Breast and Imaging Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.
Org: Memorial Sloan Kettering Cancer Center, Johns Hopkins University Bloomberg School of Public Health, Princess Margaret - University Health Network, University of Chicago Medical Center, Chicago, IL, United States Food and Drug Administration,
Abstract
Quantifying the growth of clinical actionability in precision oncology using OncoKB.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.
Org: Memorial Sloan Kettering Cancer Center, Mount Sinai Icahn School of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Yonsei Cancer Center, Yonsei University Health System, Brown University - Lifespan Cancer Institute,
Abstract
MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.
Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Summit Cancer Centers, Spokane Valley, WA, Virginia Cancer Specialists, Perlmutter Cancer Center at NYU Langone Health Medical Center,
Abstract
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.
Org: Memorial Sloan Kettering Cancer Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Columbia University Irving Medical Center, New York, NY, USA, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, New York, NY, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Org: Sorbonne University and Saint-Antoine Hospital, Mayo Clinic, Monash University School of Public Health and Preventive Medicine, Cardiff University School of Medicine, University of Pisa, Pisa, Italy,
Abstract
Characterization of diverse targetable alterations in ERBB2 and ERBB3 in 93,465 non-small cell lung cancers (NSCLC).
Org: Memorial Sloan Kettering Cancer Center, Foundation Medicine, Inc., Cambridge, MA, University of California San Diego, Moores Cancer Center,
Abstract
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
Org: Memorial Sloan Kettering Cancer Center, Centre Hospitalier Lyon Sud, Hopital Bretonneau, Karolinska University Hospital at Huddinge, University of Navarra,
Abstract
Large-scale clinicogenomic models of solid tumor CNS metastasis.
Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.
Org: Breast Service, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Biostatistics Service,
Abstract
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.
Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Henry Ford Cancer Institute, Detroit, MI, University of Colorado Denver Anschutz Medical Center, Dana-Farber Cancer Institute,
Abstract
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Org: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Department of Hematology and Cancer Prevention, Medical University of Silesia, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Memorial Sloan Kettering Cancer Center,
Abstract
Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Org: Mass General Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Arcus Biosciences, Gilead Sciences, Inc., Memorial Sloan Kettering Cancer Center,
Abstract
First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.
Org: Memorial Sloan Kettering Cancer Center, Peter MacCallum Cancer Centre, Melbourne, Australia, St Vincent’s Hospital, CHRU de Nancy - Hopitaux de Brabois, Jean Perrin Cancer Center,
Abstract
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, University of Colorado Health Science Center, University of California Los Angeles,
Abstract
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
Org: Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute, Florida Cancer Specialists and Research Institute, Ocala, FL, Memorial Sloan Kettering Cancer Center,
Abstract
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
Org: Memorial Sloan Kettering Cancer Center, University of Wisconsin, Madison, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, University of California Irvine, Sarah Cannon and HCA Research Institute,
Abstract
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.
Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists & Research Institute,
Abstract
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
Org: MSKCC, Memorial Sloan Kettering Cancer Center,
Abstract
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.
Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.
Org: Gynecologic Medical Oncology Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastro-esophageal adenocarcinoma: A phase II trial.
Org: McGill University Health Center, Montréal, QC, Canada, QC Kinetix, Canada's Michael Smith Genome Sciences Centre, Research Institute of McGill University Health Centre,
Abstract
Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.
Org: Stanford Cancer Institute, Harvard Medical School, University of California San Francisco School of Medicine, Harvard University, Tulane University School of Medicine,
Abstract
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
Org: Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Rogel Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Bashkir State Medical University,
Abstract
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Org: Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Johannes-Gutenberg University Clinic, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Fundacion Arturo López Pérez,
Abstract
Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.
Org: National Cancer Institute/National Institutes of Health, Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, Lehigh Valley Health Network,
Clinical trial
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Status: Terminated, Estimated PCD: 2022-12-30
Clinical trial
A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Phase Ib Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Pembrolizumab in Combination With Gemcitabine for Previously Treated Mycosis Fungoides and Sézary Syndrome: Efficacy and Characterization of Immune Response
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Discovery and Characterization of Susceptibility Genes in Adults and Children With Suspected Hereditary Cancer Predisposition
Status: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
Pasireotide Treatment for Patients With Prolactinomas Who Need Treatment Beyond Dopamine Agonist Therapy
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase I/II Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2023-05-02
Clinical trial
A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase I Trial of T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase 1b Study of the Safety of Concurrent Cabozantinib and Nivolumab With Radiation Therapy for Brain Metastases in Patients With Metastatic Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
CD8+ Cell Imaging During Neoadjuvant ImmunoTherapy (The C-IT Neo Trial)
Status: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2029-08-01
Clinical trial
Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Status: Completed, Estimated PCD: 2024-05-16
Clinical trial
A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Status: Completed, Estimated PCD: 2023-09-27
Abstract
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, University of California at Los Angeles, Massachusetts General Hospital, University of Iowa Hospitals & Clinics,
Abstract
Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.
Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Colorectal Service, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
“It was so many hoops to jump through”: Patient-reported administrative burden from disability, Family and Medical Leave Act (FMLA), and insurance appeals.
Org: Memorial Sloan Kettering Cancer Center, Breastcancer.org, Lankenau Institute for Medical Research, Maimonides Medical Center, Brooklyn, NY,
Abstract
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).
Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Sarcoma Medical Oncology Service,
Abstract
Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy.
Org: Memorial Sloan Kettering Cancer Center, Nuvance Health system, Nuvance Health Systems, Norris Cotton Cancer Center at Dartmouth Hitchcock,
Abstract
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Org: Université de Montréal, McGill University Health Center, Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Génomique fonctionnelle, CNRS, University of MontpellierOncology, Institute of Oncology Ljubljana,
Abstract
Machine learning-based multimodal prediction of prognosis in patients with resected intrahepatic cholangiocarcinoma.
Org: Owkin France, Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals, Inc.,
Abstract
Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD).
Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Brown University–ECOG-ACRIN Biostatistics Center, Brown University - Lifespan Cancer Institute, University of Massachusetts Lowell,
Abstract
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).
Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,
Abstract
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center/NewYork-Presbyterian,
Abstract
High-risk constitutional MLH1 methylation as a cause of early-onset colorectal and endometrial cancers displaying mismatch repair deficiency and MLH1 methylation.
Org: Cedars-Sinai Medical Center, Stanford University School of Medicine, Stanford Health Care, University of New Mexico Comprehensive Cancer Center, Inova Schar Cancer Institute,
Abstract
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
Org: Memorial Sloan Kettering Cancer Center, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Seoul National University Hospital, Hospital Quirón Madrid, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Should I stay, or should I go? Factors associated with intent to leave academic oncology.
Org: University of California San Francisco, University of Utah, Dana-Farber Cancer Institute, Harvard Medical School, Memorial Sloan Kettering Cancer Center,
Abstract
Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health.
Org: Memorial Sloan Kettering Cancer Center, Flatiron Health, San Francisco, CA, Perelman School of Medicine,
Abstract
Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.
Org: University of California San Francisco, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Dana-Farber/Brigham and Women's Cancer Center, San Francisco VA Medical Center, University of Florida Health Shands Hospital,
Abstract
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.
Org: Memorial Sloan Kettering Cancer Center, START Midwest, Grand Rapids, MI, Valkyrie Clinical Trials, Inc, Stanford Hospital & Clinics, Virginia Cancer Specialists,
Abstract
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering - Breast and Imaging Center, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.
Org: Memorial Sloan Kettering Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, City of Hope Comprehensive Cancer Center, University of California Los Angeles Translational Oncology Research,
Abstract
ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.
Org: Adult Bone Marrow Transplant Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Myeloma Service, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results.
Org: Memorial Sloan Kettering Cancer Center, Sylvester Comprehensive Cancer Center, Miami, FL, HonorHealth Research Institute, MD Anderson Cancer Center, University of California Irvine,
Abstract
Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy.
Org: Memorial Sloan Kettering Cancer Center, Chung-Ang University College of Medicine, Chung-Ang University Hospital, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.
Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Virginia Cancer Specialists, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Massachusetts General Hospital, Boston Pharmaceuticals,
Abstract
Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapy.
Org: Memorial Sloan Kettering Cancer Center, Cleveland Clinic Taussig Cancer Instititute, New York City Health and Hospital Corporation/Lincoln, Montefiore Einstein Center for Cancer Care,
Abstract
TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, University of Wisconsin Carbone Cancer Center,
Abstract
A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.
Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Memorial Sloan Kettering Cancer Center, Bayer Consumer Care AG, Bayer HealthCare Pharmaceuticals Inc.,
Abstract
Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis.
Org: Memorial Sloan Kettering Cancer Center, Elevance Health, Humana, CVS Health, Texas A&M University,
Abstract
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Hematology, University of California San Francisco, Icahn School of Medicine, Mount Sinai, Onc/Hem Care Inc, Center for Discovery and Innovation, Hackensack Meridian Health,
Abstract
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
Org: Moffitt Cancer Center, University of Washington & Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, CHU Rennes, Université Rennes,
Abstract
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Guardant Health, Inc., Palo Alto, CA, Redwood City, CA,
Abstract
Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).
Org: Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital/Massachusetts General Hospital, Department of Epidemiology & Biostatistics, Mount Sinai Morningside West, Icahn School of Medicine at Mount Sinai Morningside/West,
Abstract
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.
Org: Memorial Sloan Kettering Cancer Center, Sorbonne University and Saint-Antoine Hospital, Pitié Salpêtrière Hospital, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.
Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Lake Erie College of Osteopathic Medicine,
Abstract
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, NewYork-Presbyterian/Weill Cornell Medical Center, Duke Cancer Institute, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Memorial Sloan Kettering Cancer Center,
Abstract
Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT Carcinoma Registry.
Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, The Sarah Cannon Research Institute, Division of Hematology/Oncology, Henry Ford Health System, Pfizer, Inc.,
Abstract
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).
Org: Vanderbilt-Ingram Cancer Center, University of Texas MD Anderson Cancer Center, University of Pennsylvania-Abramson Cancer Center, Cleveland Clinic Taussig Cancer Instititute, Massachusetts General Hospital Cancer Center and Harvard Medical School,
Abstract
A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.
Org: Columbia University Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.
Org: Hospital of the University of Pennsylvania, Hunstman Cancer Institute at the University of Utah, University of Utah, Memorial Sloan Kettering Cancer Center, Celldex Therapeutics,
Abstract
Association of state policies regulating short-term limited-duration insurance plans and cancer stage at diagnosis.
Org: Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Hunstman Cancer Institute at the University of Utah, American Cancer Society, Memorial Sloan Kettering Cancer Center,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis.
Org: McGill University Health Center, Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS Fondazione Pascale, Memorial Sloan Kettering Cancer Center, Department of Pathology, Memorial Sloan Kettering Cancer Center,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions.
Org: Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CHUM,
Abstract
Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.
Org: Yale School of Medicine, Emory University, Atlanta, GA, USA, Memorial Sloan Kettering Cancer Center, Dartmouth-Hitchcock Medical Center, Yale University, General Internal Medicine,
Abstract
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.
Org: Massachusetts Eye and Ear Infirmary, Harvard Medical School, Northshore University Healthsystem, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).
Org: Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
Org: USF Health Morsani College of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, MSKCC,
Abstract
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
Org: H. Lee Moffitt Cancer Center and Research Institute, University of Miami Sylvester Cancer Center, Ronald Reagan UCLA Medical Center, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, Colorado Blood Cancer Institute and Sarah Cannon Research Institute,
Abstract
Multi-cancer brain metastasis risk score development and validation using 220,246 whole transcriptomes and machine learning.
Org: Caris Life Sciences, Irving, TX, Duke Cancer Institute, Magee-Womens Hospital of UPMC/ UPMC Hillman Cancer Center, Penn State Milton S. Hershey Medical Center, Hershey, PA, Massachusetts General Hospital,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, University of Pittsburgh Cancer Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Memorial Sloan Kettering Cancer Center,
Abstract
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.
Org: Northwestern University Robert H. Lurie Comprehensive Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Org: Memorial Sloan Kettering Cancer Center, Washington University School of Medicine in St Louis, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, University of Southern California, Norris Comprehensive Cancer Center, Norton Medical Group,
Abstract
The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy.
Org: Memorial Sloan Kettering Cancer Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
Org: University of Miami Miller School of Medicine, Miami, FL, Sylvester Comprehensive Cancer Center, Miami, FL, Miami, FL, Servier Pharmaceuticals, Boston, MA,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Org: MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Asan Medical Center, Hammersmith Hospital, Imperial College, London, United Kingdom, Department of Gastroenterology/Digestive Oncology,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Are we ready to mitigate time toxicity of cancer care? Oncologists’ perceptions on digital interventions to fast-track cancer care.
Org: Memorial Sloan Kettering Cancer Center, Penn Abramson Cancer Center, Abramson Cancer Center, University of Pennsylvania, Department of Family Medicine & Community Health, PSOM, University of Pennsylvania Health System,
Abstract
18F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBG.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Org: Memorial Sloan Kettering Cancer Center, University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.
Org: UPMC Hillman Cancer Center, HonorHealth Research Institute, City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University Hospital Siedman Cancer Center,
Abstract
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.
Org: BC Cancer-Vancouver Centre, Vancouver Prostate Centre, Tulane Cancer Center, Gustave Roussy Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis.
Org: National Cancer Institute, Vilnius, Lithuania, Memorial Sloan Kettering Cancer Center, National Institutes of Health All of Us Research Program,
Abstract
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Org: NHMRC Clinical Trials Centre, The University of Sydney, Peter MacCallum Cancer Centre, Melbourne, Australia, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02).
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Netherlands Cancer Institute, Amsterdam, Netherlands, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).
Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Myeloma, Memorial Sloan Kettering Cancer Center, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.
Org: City of Hope National Medical Center, Genentech, BC Cancer Centre for Lymphoid Cancer, Centre Henri-Becquerel and University of Rouen, University Hospital Münster,
Abstract
Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?
Org: Weill Cornell Medicine - Qatar, Doha, Qatar, Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.
Org: University of Pennsylvania, Basser Center for BRCA, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic,
Abstract
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, MSKCC, New York Proton Center, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey,
Abstract
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Org: Columbia University Irving Medical Center, New York, NY, USA, Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Intrathecal drug delivery systems for cancer pain control: Insights on current contemporary practices in the US.
Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Department of Anesthesiology and pain medicine, Seoul National University Bundang Hospital, Seongnam-Si, South Korea, Memorial Sloan Kettering Cancer Center,
Abstract
Accelerated partial breast irradiation (APBI) for ductal carcinoma in situ.
Org: Memorial Sloan Kettering Cancer Center, Montvale, New York Oncology Hematology PC, Tarrytown, NY, MSKCC,
Abstract
Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial.
Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, University of California Irvine, San Diego State University Department of Biology, San Diego, CA, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey,
Abstract
Rates of emergency department visits and acute-care hospital admissions after starting chemotherapy or having surgery across six community-based cancer centers.
Org: Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, MaineHealth Cancer Care, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, WVU Cancer Institute,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.
Org: Washington University School of Medicine in St Louis, Stanford Cancer Center, Centre Léon Bérard, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Prevalence and patterns of breast white adipose tissue inflammation among American Black women and indigenous Nigerian women with early-stage breast cancer.
Org: Weill Cornell Medical Center/NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center, Obafemi Awolowo University, African Research Group for Oncology, OAUTHC,
Abstract
A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.
Org: Memorial Sloan Kettering Cancer Center, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sarcoma Medical Oncology Service,
Abstract
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.
Org: Memorial Sloan Kettering Cancer Center, Vanderbilt University School of Medicine, DELFI Diagnostics, Medical College of Wisconsin,
Abstract
A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor.
Org: LUMC Leids Universitair Medisch Centrum, Chris O'Brien Lifehouse, University of California, Davis, Ohio State University Comprehensive Canvcer Hospital, Sarcoma Medical Oncology Service,
Abstract
Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Evaluation of a mobile behavior change program for weight loss in breast cancer survivors: A prospective single-arm pilot study.
Org: Memorial Sloan Kettering Cancer Center, Noom, Inc.,
Abstract
Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabis.
Org: Memorial Sloan Kettering Cancer Center, MSKCC, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Hartford hospital, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Abstract
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
Org: Lung Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Sarah Cannon Research Institute at HealthONE, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer.
Org: Memorial Sloan Kettering Cancer Center, Renaissance School of Medicine at Stony Brook University, School of Health Science, Stockton University,
Abstract
Racial and ethnic disparities in employment of patients and caregivers following breast cancer diagnosis.
Org: Breastcancer.org, Lankenau Institute for Medical Research, Maimonides Medical Center, Brooklyn, NY, Outcomes Insights, Memorial Sloan Kettering Cancer Center,
Abstract
Use of statistical process control charts to identify impactful implementation strategies for an ePRO-based symptom management program across the SIMPRO Consortium.
Org: Dana-Farber Cancer Institute, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, WVU Cancer Institute, MaineHealth Cancer Care, Dartmouth-Hitchcock Medical Center,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.
Org: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Margaret Cancer Centre,
Abstract
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
Org: Memorial Sloan Kettering Cancer Center, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group, Mayo Clinic,
Abstract
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).
Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,
Abstract
Reduction in Curie score in neuroblastoma patients treated with naxitamab.
Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Hong Kong Children's Hospital, The University of Hong Kong, The Hospital for Sick Children,
Abstract
INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.
Org: Dana-Farber Cancer Institute, Centre Léon Bérard, Memorial Sloan Kettering Cancer Center, Sarcoma Unit, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.
Org: Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health, Georgetown Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Innovation Center for Biomedical Informatics (ICBI),
Abstract
Oncologic outcomes in patients with radiation associated rectal adenocarcinoma.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.
Org: University of Linköping, Linköping University Hospital, Sweden, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences,
Abstract
Early integration of exercise into breast cancer care: The MSK Healthy Living program.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.
Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.
Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, Spectrum Medical Group, Columbia University Irving Medical Center, New York, NY, USA, Columbia University Medical Center,
Abstract
Predictors of benefit to radiation for oligoprogressive disease in EGFR-mutant metastatic non-small cell lung cancer patients treated with osimertinib.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Real-world utilization pattern of pexidartinib in patients with tenosynovial giant cell tumor (TGCT).
Org: Daiichi Sankyo Inc., IQVIA, Amsterdam, Netherlands, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center,
Abstract
3D genomics identify alternate mechanisms of homologous recombination deficiency in uterine sarcoma.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, NYU Langone Health, New York, NY, King Edward Memorial Hospital, Perth, Australia,
Abstract
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, HonorHealth Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Unmasking ethnic disparities in Asian representation in U.S. oncology training programs.
Org: Memorial Sloan Kettering Cancer Center, Winship Cancer Institute, Emory University School of Medicine, Huntsman Cancer Institute, Johns Hopkins University Bloomberg School of Public Health, Abramson Cancer Center,
Abstract
The Onc Docs: Partnering with Black cancer patients for cancer education.
Org: Memorial Sloan Kettering Cancer Center, New York Presbyterian/Weill Cornell Medical Center,
Abstract
Dermocosmetics in management of cancer-related skin toxicities: International expert consensus.
Org: Nantes Université, University of Queensland Diamantina Institute, Hospital Alemao Oswaldo Cruz, Departments of Dermatology & Radiation Oncology, La-Roche Posay International,
Abstract
An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.
Org: McGill University Health Center, The Second Affiliated Hospital Of Nanchang University, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center,
Clinical trial
Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Diffuse Pleural Mesothelioma
Status: Recruiting, Estimated PCD: 2029-06-21
Clinical trial
Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers
Status: Recruiting, Estimated PCD: 2024-10-01
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.
Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,
Abstract
A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).
Org: Memorial Sloan Kettering Cancer Center, Cleveland Clinic Taussig Cancer Instititute,
Abstract
A multi-center natural history study of precision-based genomics in prostate cancer (PC).
Org: Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Memorial Sloan Kettering Cancer Center, University of California San Diego,
Abstract
Pan-cancer landscape of FOXA1 alterations: Insights and clinical implications.
Org: Memorial Sloan Kettering Cancer Center, University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Desai Sethi Urology Institute at the University of Miami and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, University of Massachusetts Medical School,
Abstract
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Cornell University, National University Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Jewish General Hospital Stroll Cancer Prevention Centre, Centre Hospitalier de l’Universite de Montreal, University of Pennsylvania Perelman School of Medicine, Princess Margaret Hospital,
Abstract
Clinical and genomic landscape of EGFR-mutant lung cancers (LCs) with squamous and adenosquamous differentiation.
Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Memorial Sloan Kettering Cancer Center,
Abstract
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center and Weill Cornell College of Medicine,
Abstract
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.
Org: Memorial Sloan Kettering Cancer Center, Weill Medical College,
Abstract
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
Org: Weill Cornell Medicine - Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Memorial Sloan Kettering Cancer Center,
Abstract
First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.
Org: Memorial Sloan Kettering Cancer Center, Macquarie University, Volga District Medical Center, Federal Medical-Biological Agency, Medical Oncology Group,
Abstract
CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.
Org: City of Hope National Medical Center, John Wayne Cancer Institute, University of Washington and Fred Hutchinson Cancer Research Centre, CARTI Cancer Center, ImaginAb,
Abstract
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,
Abstract
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
Org: MD Anderson Cancer Center, Bristol Myers Squibb, Evidera, Inc, Seràgnoli Institute of Hematology, Winship Cancer Center of Emory University,
Abstract
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,
Abstract
Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell College of Medicine, Weill Medical College,
Abstract
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.
Org: Dana-Farber Cancer Institute, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Janssen Research & Development,
Abstract
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).
Org: Alliance Statistics and Data Management Center, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey, Dana-Farber Cancer Institute,
Abstract
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
Org: City of Hope- Long Beach Elm, Perlmutter Cancer Center, New York University Langone Health, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, Northwestern Medicine Devleopmental Therapeutics Institute,
Abstract
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
Org: University of California, San Francisco Medical Center, University of North Carolina, Lineberger Comprehensive Cancer Center, University of Chicago, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Duke Cancer Institute,
Abstract
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
Org: Memorial Sloan Kettering Cancer Center, MSKCC, Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Adult Bone Marrow Transplant Service,
Abstract
Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).
Org: James P. Wilmot Cancer Center/URMC - JPWCC, Memorial Sloan Kettering Cancer Center,
Abstract
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.
Org: University of California San Francisco, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Hackensack University Medical Center, Portland VA Health Care System and OHSU Knight Cancer Institute,
Abstract
Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.
Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY,
Abstract
A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant.
Org: Washington University School of Medicine in St Louis, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Invivoscribe, Inc.,
Abstract
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.
Org: Thompson Cancer Survival Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, City of Hope Comprehensive Cancer Center, Earle A Chiles Research Institute, Cedars-Sinai Cancer,
Abstract
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
Org: Novartis Pharma AG, Novartis Oncology, Genesis Research, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yale School of Medicine,
Abstract
A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).
Org: Zentalis Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The James Cancer Hospital and Solove Research Institute, University of Texas M.D. Anderson Cancer Center,
Abstract
Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).
Org: Memorial Sloan Kettering Cancer Center, Resolution Bioscience, Agilent,
Abstract
A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.
Org: Memorial Sloan Kettering Cancer Center, NYU Medical Center-Perlmutter Cancer Center,
Abstract
Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.
Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Clinical Oncology Center, Polytechnic University of Marche,
Abstract
The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
Org: Memorial Sloan Kettering Cancer Center, Merck & Co, Inc., Linnaeus Therapeutics, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.
Org: Memorial Sloan Kettering Cancer Center, Immunocore Ltd., Massachusetts General Hospital, Institut Curie, Saint Cloud, France, Mount Vernon Cancer Center,
Abstract
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Princess Margaret Cancer Centre, University of Toronto,
Abstract
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lombardi Comprehensive Cancer Center, University of Berne and Cantonal Hospital of Lucerne,
Abstract
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Memorial Sloan Kettering Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy in survivors of cancer.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.
Org: La Roche-Posay International, Levallois-Perret, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, Memorial Sloan Kettering Cancer Center,
Abstract
Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.
Org: Memorial Sloan Kettering Cancer Center, Hartford Healthcare Medical Group, Hartford Healthcare Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Medicine, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Harvard Medical School, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
Org: MGH Cancer Center, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Medical College of Wisconsin, Norris Comprehensive Cancer Center,
Abstract
Empathic communication skills training: Randomized controlled trial to reduce lung cancer stigma in lung cancer care.
Org: Memorial Sloan Kettering Cancer Center, GO2 for Lung Cancer, American Cancer Society,
Abstract
Patient- versus clinician-reported symptoms in the POLARIX study.
Org: Mayo Clinic College of Medicine, Washington University School of Medicine in St Louis, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center, Centre Henri-Becquerel and University of Rouen,
Abstract
Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort.
Org: Karmanos Cancer Institute, Wayne State University, Memorial Sloan Kettering Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Roswell Park Comprehensive Cancer Center,
Abstract
Palliative care as a component of high-value and cost-saving care during hospitalization for metastatic cancer.
Org: Suny Downstate Health Sciences University, Sunnybrook Health Sciencies, Princess Margaret Cancer Centre, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University of Toronto,
Abstract
Serum cytokines and autoantibodies to GM-CSF and immune-related colitis in ipilimumab-treated patients with cancer.
Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Hospital-Breast Medical Oncology, Memorial Sloan Kettering Cancer Center, Precision Immunology Institute, The Tisch Cancer Institute at Mount Sinai Health System,
Abstract
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
Org: Memorial Sloan Kettering Cancer Center, Sarcoma Medical Oncology Service,
Abstract
Cannabis use among recently treated cancer patients: Perceptions and experiences.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Children's Hospital Colorado, Aurora, CO,
Abstract
Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Harvard Medical School, University Hospital Essen,
Abstract
Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR).
Org: Memorial Sloan Kettering Cancer Center, University of Wisconsin Carbone Cancer Center, University of Virginia Comprehensive Cancer Center,
Abstract
The patient experience of prior authorization for cancer care: Anxiety, delays, and the erosion of trust.
Org: Memorial Sloan Kettering Cancer Center, City College of New York, EGFR Resisters,
Abstract
Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology setting: A retrospective observational study.
Org: Compass Oncology, Merck & Co., Inc., Ontada, Memorial Sloan Kettering Cancer Center, AstraZeneca,
Abstract
Healthcare coverage, access, and affordability among adult immigrant cancer survivors in the United States.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Washington University School of Medicine in St. Louis, St. Louis, MO,
Abstract
Self-reported overall wellbeing and physical function among chemotherapy and surgery patients completing symptom questionnaires across six health systems.
Org: Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dartmouth-Hitchcock Medical Center, MaineHealth Cancer Care, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Org: UPMC Hillman Cancer Center, University of Oklahoma Stephenson Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Assessing changes in cancer-related financial support needs across three waves of the COVID-19 pandemic.
Org: Memorial Sloan Kettering Cancer Center, Family Reach Foundation, Texas A&M University School of Medicine,
Abstract
Commercial vs. Medicaid insurance and use of high-priced anticancer treatments.
Org: Memorial Sloan Kettering Cancer Center, Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Vanderbilt University School of Medicine, UNC Gillings School of Global Public Health,
Abstract
Integrating technology to support data management abstraction of adverse events (AE) and concomitant medications (ConMed) from the electronic health record (EHR) to sponsor electronic data capture (EDC) systems using design thinking (DT) methodology.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Pittsburgh Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Rogel Cancer Center, University of Michigan, Aix-Marseille University CHU Timone,
Abstract
Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer.
Org: Memorial Sloan Kettering Cancer Center, Epic Sciences, Inc.,
Abstract
Survivorship in patients with cardiac metastases defined by cardiac magnetic resonance imaging in relation to lesion hypoperfusion.
Org: Weill Cornell Medical College University, New York, NY, Memorial Sloan Kettering Cancer Center, Sarcoma Medical Oncology Service,
Abstract
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.
Org: University Hospitals Leuven, Leuven, Belgium, Leuven Cancer Institute, BGOG, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Copenhagen University Hospital,
Abstract
Targeting CD47 in lymphoid malignancies with CAR T cells.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Tumor immune infiltrates and overall survival in non-small cell lung cancer are associated with an unsupervised radiomic signature.
Org: Memorial Sloan Kettering Cancer Center, Stony Brook University Hospital - Cancer Center,
Abstract
Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).
Org: Weill Cornell Medical Center/New York Presbyterian, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).
Org: University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, University of Rochester Medical School, AdventHealth Orlando,
Abstract
Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting.
Org: EMD Serono Research & Development Institute, Rockland, MA, Genesis Research, Hoboken, NJ, Memorial Sloan Kettering Cancer Center,
Abstract
Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.
Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Department of Thoracic Oncology, Peking University Cancer Hospital, IRCCS Humanitas Research Hospital, Rozzano, Italy,
Abstract
Enhancing patient clinical streamlining (EPACS) pilot in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center.
Org: Mount Sinai Morningside and West, NYU Langone Health, New York, NY, Memorial Sloan Kettering Cancer Center,
Abstract
Association of cannabis use with real-world time to treatment discontinuation (rwTTD) in patients with advanced cancer initiating immune checkpoint inhibition (ICI).
Org: HealthPartners Institute, Memorial Sloan Kettering Cancer Center, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Forian Inc.,
Abstract
Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES).
Org: Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, UM/Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets).
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.
Org: Vall d’Hebron Institute of Oncology (VHIO), Ludwig-Maximilians-University Hospital, University of Eastern Piedmont, Institut Català D'Oncologia, IDIBELL,
Clinical trial
A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
Status: Active (not recruiting), Estimated PCD: 2025-07-01